Imunon Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
IMNN$0.77-12.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(18,620,242) | $(19,514,977) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 240,175 | 248,154 |
| Amortization of right-of-use assets | 477,941 | 471,851 |
| Realized and unrealized (gains) and losses, net, on investment securities | (61,983) | 34,302 |
| Stock-based compensation | 477,256 | 759,013 |
| Realization of deferred income tax asset | 1,280,385 | 286,641 |
| Loss on extinguishment of debt | - | 329,158 |
| Write-off of note receivable (Transomic) | - | 375,000 |
| Amortization of deferred finance charges and debt discount associated with note payable | - | 55,122 |
| Net changes in: | ||
| Accrued interest receivable on investment securities | - | 68,136 |
| Advances, deposits, and other current assets | 408,859 | (141,619) |
| Accounts payable and accrued liabilities | (3,057,361) | (1,992,929) |
| Net cash used in operating activities | (18,854,970) | (19,022,148) |
| Cash flows from investing activities: | ||
| Purchases of investment securities | (57,174) | (13,541,806) |
| Proceeds from sale and maturity of investment securities | 9,915,448 | 25,000,000 |
| Purchases of property and equipment | (29,541) | (451,759) |
| Net cash provided by investing activities | 9,828,733 | 11,006,435 |
| Cash flows from financing activities: | ||
| Proceeds from sale of common stock equity, net of issuance costs | 9,060,438 | 2,781,438 |
| Payoff of the SVB loan and accrued end-of-term fees | - | (6,420,000) |
| Net cash (used in) provided by financing activities | 9,060,438 | (3,638,562) |
| Net change in cash, cash equivalents and restricted cash | 34,201 | (11,654,275) |
| Cash, cash equivalents and restricted cash at beginning of year | 5,838,566 | 17,492,841 |
| Cash and cash equivalents end of year | $5,872,767 | $5,838,566 |
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Continued)
| Years Ended December 31, | |||
|---|---|---|---|
| 2024 · 2023 | |||
| Supplemental disclosure of cash flow information: | |||
| Cash paid for: | |||
| Interest | $ | - | $179,542 |
| Non-Cash Investing and Financing Activities | |||
| Recognition of right of use asset and liability | $ | - | $1,911,049 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.